ALAMEDA, Calif.--(BUSINESS WIRE)--Celera (NYSE:CRA), an Applera Corporation business, today announced the publication of results from the Atherosclerosis Risk in Communities (ARIC) study and two independent case-control studies describing the development of a Genetic Risk Score™ (GRS) based on five gene variants that predicts risk for coronary heart disease (CHD). These variant genes were KIF6, MYH15, PALLD, SNX19, and VAMP8. The GRS of each ARIC participant depended on how many of these risk variants an individual had. After adjusting for traditional risk factors, those individuals with a high risk GRS had a 57% increased risk of incident CHD, which is similar to the magnitude of risk for CHD associated with smoking, hypertension, hypercholesterolemia, or obesity.
